Back to resultsA Study to Assess the Safety of BIIB122 Tablets and if it Can Slow the Worsening of Early-Stage Parkinson's Disease in Participants Between the Ages of 30 and 80 (LUMA)
Primary Purpose
Parkinson Disease
Status
Recruiting
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
BIIB122
BIIB122-Matching Placebo
Sponsored by
About this trial
This is an interventional treatment trial for Parkinson Disease focused on measuring Early-stage Parkinson Disease
Eligibility Criteria
Key Inclusion Criteria:
- Clinical diagnosis of PD meeting the Movement Disorder Society Clinical Diagnostic Criteria within 2 years of the Screening Visit, inclusive, and at least 30 years of age at the time of diagnosis
- Modified Hoehn and Yahr scale stages 1 to 2 (in OFF state), inclusive, at screening
- MDS-UPDRS Parts II and III (in OFF state) combined score less than or equal to (≤)40 at screening
- Screening genetic test results verifying the absence of a pathogenic leucine-rich repeat kinase 2 (LRRK2) variant. Confirmation of this eligibility requirement may come from an accredited genetic test that includes all exclusionary LRRK2 genetic variants.
Key Exclusion Criteria:
- Clinically significant neurological disorder other than PD, including but not limited to stroke, dementia, or seizure, within 5 years of screening visit, in the opinion of the Investigator
- Clinical evidence of atypical parkinsonism (e.g., multiple-system atrophy or progressive supranuclear palsy) or evidence of drug-induced parkinsonism.
- Montreal Cognitive Assessment (MoCA) score <24 at the screening visit
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Sites / Locations
- Mayo Clinic ArizonaRecruiting
- Banner Sun Health Research InstituteRecruiting
- Cedars SinaiRecruiting
- SC3 Research Group Inc.Recruiting
- University of California San Francisco (UCSF)Recruiting
- University of ColoradoRecruiting
- CenExel Rocky Mountain Clinical ResearchRecruiting
- Institute for Neurodegenerative Disorders (IND)Recruiting
- Parkinson's Disease and Movement Disorders Center of Boca RatonRecruiting
- University of MiamiRecruiting
- Adventist Health System/Sunbelt, Inc.Recruiting
- USF Health Byrd InstituteRecruiting
- Hawaii Pacific Neuroscience, LLCRecruiting
- Northwestern UniversityRecruiting
- Rush University Medical CenterRecruiting
- University of Kansas Medical Center Research Institute, Inc.Recruiting
- Boston University Medical CenterRecruiting
- Beth Israel Deaconess Medical CenterRecruiting
- Massachusetts General HospitalRecruiting
- Quest Research InstituteRecruiting
- Mount Sinai Beth IsraelRecruiting
- Weill Medical College of Cornell UniversityRecruiting
- Duke Movement Disorders ClinicRecruiting
- The Cleveland Clinic FoundationRecruiting
- UPHSRecruiting
- University of PittsburghRecruiting
- Medical University of South CarolinaRecruiting
- Neurology Clinic, PCRecruiting
- The Methodist Hospital Research InstituteRecruiting
- Virginia Commonwealth University Department of NeurologyRecruiting
- Evergreen Hospital Medical CenterRecruiting
- Inland Northwest ResearchRecruiting
- Medizinische UniversitätRecruiting
- Klinik OttakringRecruiting
- University of CalgaryRecruiting
- True North Clinical ResearchRecruiting
- Toronto Western HospitalRecruiting
- CHUM Centre de RechercheRecruiting
- Montreal Neurological InstituteRecruiting
- Xuanwu Hospital Capital Medical UniversityRecruiting
- Beijing HospitalRecruiting
- Second Affiliated Hospital of Soochow UniversityRecruiting
- West China Hospital, Sichuan UniversityRecruiting
- Hôpital de la TimoneRecruiting
- Hopital PurpanRecruiting
- Hopital Gui de ChauliacRecruiting
- CHU Rennes - Hopital PontchaillouRecruiting
- CHU Clermont Ferrand - Hopital Gabriel MontpiedRecruiting
- Centre Hospitalier Universitaire de Lyon-Hospices Civils de Lyon-Hopital Pierre WertheimerRecruiting
- CHU Nantes - Hopital Nord LaënRecruiting
- Groupe Hospitalier Pitie-SalpetriereRecruiting
- Hopital Henri MondorRecruiting
- Universitat UlmRecruiting
- Katholisches Klinikum BochumRecruiting
- Universitaetsklinikum WuerzburgRecruiting
- Medizinische Hochschule HannoverRecruiting
- Katholisches Klinikum Bochum gGmbHRecruiting
- Universitaetsklinikum Duesseldorf AoeRRecruiting
- Universitaetsklinikum Carl Gustav Carus TU DresdenRecruiting
- Paracelsus-Elena-Klinik KasselRecruiting
- Universitätsklinikum MarburgRecruiting
- Universitaetsklinikum TuebingeRecruiting
- Rabin Medical CenterRecruiting
- Center Chaim Sheba Medical CenterRecruiting
- Tel Aviv Sourasky Medical CenterRecruiting
- I.R.C.C.S. NeuromedRecruiting
- IRCCS-Institute of Neurological Sciences of BolognaRecruiting
- Azienda Ospedaliera SpedaliRecruiting
- U.O. Neurologia IRecruiting
- Ospedale Clinicizzato SS. AnnuRecruiting
- Ospedale San RaffaeleRecruiting
- AO Universitaria PisanaRecruiting
- IRCCS San Raffaele PisanaRecruiting
- Okinawa Prefectural NanbuRecruiting
- NHO Asahikawa Medical CenterRecruiting
- Himeji CentralRecruiting
- Sendai Nishitaga National HospitalRecruiting
- Juntendo UniversityRecruiting
- Brain Research Center AmsterdamRecruiting
- RadboudumcRecruiting
- Brain Research Center Zwolle B.V.Recruiting
- Centrum Medyczne NeuroProtectRecruiting
- Centrum Medyczne NeuromedRecruiting
- Instytut Zdrowia dr Boczarska-Jedynak sp.z.o.o, Sp.KRecruiting
- Nzoz Novo-MedRecruiting
- MD Clinic PragaRecruiting
- INSULA Centrum Badan KlinicznychRecruiting
- Hospital General de CatalunyaRecruiting
- Clinica Universidad de NavarraRecruiting
- Complejo Hospitalario Universitario A CoruñaRecruiting
- Hospital de CrucesRecruiting
- Hospital Universitari Vall d'HebronRecruiting
- Hospital Clinic de BarcelonaRecruiting
- Hospital de la Santa Creu i Sant PauRecruiting
- Hospital Universitario de La PrincesaRecruiting
- Policlinica GipuzkoaRecruiting
- Hospital Universitario Virgen del RocioRecruiting
- University Hospitals PlymouthRecruiting
- The National Hospital for Neurology & NeurosurgeryRecruiting
- Salford Royal NHS Foundation TrustRecruiting
- Glasgow Memory Clinic LtdRecruiting
- Newcastle UniversityRecruiting
- Ninewells HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
BIIB122 225 mg
BIIB122 Matching Placebo
Arm Description
Participants will receive BIIB122, 225 mg tablets, by mouth, once daily (QD) for up to a minimum of 48 weeks and a maximum of 144 weeks. Participants who received BIIB122 and completed the ET visit of study 283PD302 (NCT05418673) will continue to receive BIIB122, 225 mg tablets, by mouth, QD for up to a minimum of 48 weeks and a maximum of 144 weeks.
Participants will receive BIIB122 matching placebo tablets, by mouth, QD for up to a minimum of 48 weeks and a maximum of 144 weeks. Participants who received placebo and completed the ET visit of study 283PD302 (NCT05418673) will continue to receive BIIB122 matching placebo tablets, by mouth, QD for up to a minimum of 48 weeks and a maximum of 144 weeks.
Outcomes
Primary Outcome Measures
Time to Confirmed Worsening in Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Parts II and III Combined Score Over the Treatment Period
Time to confirmed worsening is defined as a worsening event sustained over 2 consecutive assessments. MDS-UPDRS is a multimodal scale assessing impairment and disability consisting of 4 parts. Part II assesses motor experiences of daily living (Range 0-52). It contains 13 questions which are to be completed by the participant. Part III assesses the motor signs of PD and is administered by the rater (Range 0-132). Part III contains 33 scores based on 18 items. For each question a numeric score is assigned between 0-4, where 0 = Normal, 1 = Slight, 2 = Mild, 3 = Moderate, 4 = Severe. MDS-UPDRS Part II and III combined score equals the sum of Parts II and III (Range 0-184). A higher score indicates more severe symptoms of PD.
Secondary Outcome Measures
Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
An AE is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. An SAE is any untoward medical occurrence that at any dose results in death; in the view of the investigator, places the participant at immediate risk of death (a life-threatening event); requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; results in a congenital anomaly/birth defect or is a medically important event.
Time to Confirmed Worsening in MDS-UPDRS Part II Score Over the Treatment Period
Time to confirmed worsening is defined as a worsening event sustained over 2 consecutive assessments. MDS-UPDRS is a multimodal scale assessing impairment and disability consisting of 4 parts. Part II assesses motor experiences of daily living (Range 0-52). It contains 13 questions which are to be completed by the participant. For each question a numeric score is assigned between 0-4, where 0 = Normal, 1 = Slight, 2 = Mild, 3 = Moderate, 4 = Severe. A higher score indicates more severe symptoms of PD.
Change From Baseline in MDS-UPDRS Parts II and III Combined Score
MDS-UPDRS is a multimodal scale assessing impairment and disability consisting of 4 parts. Part II assesses motor experiences of daily living (Range 0-52). It contains 13 questions which are to be completed by the participant. For each question a numeric score is assigned between 0-4, where 0 = Normal, 1 = Slight, 2 = Mild, 3 = Moderate, 4 = Severe. A higher score indicates more severe symptoms of PD. Part III assesses the motor signs of PD and is administered by the rater (Range 0-132). Part III contains 33 scores based on 18 items. For each question a numeric score is assigned between 0-4, where 0 = Normal, 1 = Slight, 2 = Mild, 3 = Moderate, 4 = Severe. MDS-UPDRS Parts II and III combined score equals the sum of Part II and III (Range 0-184). A higher score indicates more severe symptoms of PD.
Time to Confirmed Worsening in Modified Schwab and England Activities of Daily Living Scale (mSE-ADL) Over the Treatment Period
Time to confirmed worsening is defined as a worsening event sustained over 2 consecutive assessments. The mSE-ADL scale reflects the speed, ease, and independence with which an individual performs daily activities or personal chores with 100% indicating total independence, falling to 0%, which indicates a state of complete dependence. The individual is asked to rate his or her function using an 11-point scale (10% increments), from 100% (completely independent; able to do all chores without slowness, difficulty, or impairment; essentially normal; unaware of any difficulty) to 0% (vegetative functions such as swallowing, bladder and bowels are not functioning; bedridden). The lower the score, the worse the functional status.
Change From Baseline in MDS-UPDRS Parts I, II, and III Combined Score
MDS-UPDRS is a multimodal scale assessing impairment and disability consisting of 4 parts. Part I assesses non-motor experiences of daily living and has 2 components (Range 0-52). Part IA contains 6 questions and is assessed by the examiner (Range 0-24). Part IB contains 7 questions on non-motor experiences of daily living which are to be completed by the participant (Range 0-28). Part II assesses motor experiences of daily living (Range 0-52). It contains 13 questions which are to be completed by the participant. Part III assesses the motor signs of PD and is administered by the rater (Range 0-132). Part III contains 33 scores based on 18 items. For each question a numeric score is assigned between 0-4, where 0 = Normal, 1 = Slight, 2 = Mild, 3 = Moderate, 4 = Severe. MDS-UPDRS total score equals the sum of Parts I, II, and III (Range 0-236). A higher score indicates more severe symptoms of PD.
Full Information
NCT ID
NCT05348785
First Posted
April 4, 2022
Last Updated
October 11, 2023
Sponsor
Biogen
Collaborators
Denali Therapeutics Inc.
1. Study Identification
Unique Protocol Identification Number
NCT05348785
Brief Title
A Study to Assess the Safety of BIIB122 Tablets and if it Can Slow the Worsening of Early-Stage Parkinson's Disease in Participants Between the Ages of 30 and 80
Acronym
LUMA
Official Title
A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of BIIB122 in Participants With Parkinson's Disease
Study Type
Interventional
2. Study Status
Record Verification Date
October 2023
Overall Recruitment Status
Recruiting
Study Start Date
April 19, 2022 (Actual)
Primary Completion Date
August 15, 2025 (Anticipated)
Study Completion Date
August 28, 2025 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Biogen
Collaborators
Denali Therapeutics Inc.
4. Oversight
Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
In this study, researchers will learn more about a study drug called BIIB122 in participants with early-stage Parkinson's disease (PD). In this study:
Participants will take 225 milligrams (mg) of BIIB122 or a placebo as tablets by mouth. A placebo looks like the study drug but has no real medicine in it.
Participants will take BIIB122 or placebo 1 time a day for up to a minimum of 48 weeks and a maximum of 144 weeks.
Certain medications for PD will be allowed at enrollment for a subset of participants.
The majority of clinic visits will be every 12 weeks. The main question researchers are trying to answer is if taking BIIB122 slows the worsening of symptoms more than placebo in the early stages of PD.
To help answer this question, researchers will use a questionnaire called the Movement Disorder Society-Unified Parkinson's Disease Rating Scale, also known as the MDS-UPDRS. Researchers will use the MDS-UPDRS to learn about participant PD symptoms and how they affect their daily life. Researchers will also learn more about the safety of BIIB122.
Detailed Description
BIIB122 is an investigational central nervous system-penetrant small molecule inhibitor of leucine-rich repeat kinase 2 (LRRK2). Participants who completed the early termination (ET) visit of the study 283PD302 (NCT05418673) would be eligible for screening of this study and if enrolled, these participants are not eligible for the sub studies of 283PD201.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Parkinson Disease
Keywords
Early-stage Parkinson Disease
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
640 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
BIIB122 225 mg
Arm Type
Experimental
Arm Description
Participants will receive BIIB122, 225 mg tablets, by mouth, once daily (QD) for up to a minimum of 48 weeks and a maximum of 144 weeks.
Participants who received BIIB122 and completed the ET visit of study 283PD302 (NCT05418673) will continue to receive BIIB122, 225 mg tablets, by mouth, QD for up to a minimum of 48 weeks and a maximum of 144 weeks.
Arm Title
BIIB122 Matching Placebo
Arm Type
Placebo Comparator
Arm Description
Participants will receive BIIB122 matching placebo tablets, by mouth, QD for up to a minimum of 48 weeks and a maximum of 144 weeks.
Participants who received placebo and completed the ET visit of study 283PD302 (NCT05418673) will continue to receive BIIB122 matching placebo tablets, by mouth, QD for up to a minimum of 48 weeks and a maximum of 144 weeks.
Intervention Type
Drug
Intervention Name(s)
BIIB122
Other Intervention Name(s)
DNL151
Intervention Description
Administered as specified in the treatment arm
Intervention Type
Drug
Intervention Name(s)
BIIB122-Matching Placebo
Intervention Description
Administered as specified in the treatment arm
Primary Outcome Measure Information:
Title
Time to Confirmed Worsening in Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Parts II and III Combined Score Over the Treatment Period
Description
Time to confirmed worsening is defined as a worsening event sustained over 2 consecutive assessments. MDS-UPDRS is a multimodal scale assessing impairment and disability consisting of 4 parts. Part II assesses motor experiences of daily living (Range 0-52). It contains 13 questions which are to be completed by the participant. Part III assesses the motor signs of PD and is administered by the rater (Range 0-132). Part III contains 33 scores based on 18 items. For each question a numeric score is assigned between 0-4, where 0 = Normal, 1 = Slight, 2 = Mild, 3 = Moderate, 4 = Severe. MDS-UPDRS Part II and III combined score equals the sum of Parts II and III (Range 0-184). A higher score indicates more severe symptoms of PD.
Time Frame
Up to Week 144
Secondary Outcome Measure Information:
Title
Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Description
An AE is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. An SAE is any untoward medical occurrence that at any dose results in death; in the view of the investigator, places the participant at immediate risk of death (a life-threatening event); requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; results in a congenital anomaly/birth defect or is a medically important event.
Time Frame
Up to Week 146
Title
Time to Confirmed Worsening in MDS-UPDRS Part II Score Over the Treatment Period
Description
Time to confirmed worsening is defined as a worsening event sustained over 2 consecutive assessments. MDS-UPDRS is a multimodal scale assessing impairment and disability consisting of 4 parts. Part II assesses motor experiences of daily living (Range 0-52). It contains 13 questions which are to be completed by the participant. For each question a numeric score is assigned between 0-4, where 0 = Normal, 1 = Slight, 2 = Mild, 3 = Moderate, 4 = Severe. A higher score indicates more severe symptoms of PD.
Time Frame
Up to a minimum of 48 weeks and a maximum of 144 weeks
Title
Change From Baseline in MDS-UPDRS Parts II and III Combined Score
Description
MDS-UPDRS is a multimodal scale assessing impairment and disability consisting of 4 parts. Part II assesses motor experiences of daily living (Range 0-52). It contains 13 questions which are to be completed by the participant. For each question a numeric score is assigned between 0-4, where 0 = Normal, 1 = Slight, 2 = Mild, 3 = Moderate, 4 = Severe. A higher score indicates more severe symptoms of PD. Part III assesses the motor signs of PD and is administered by the rater (Range 0-132). Part III contains 33 scores based on 18 items. For each question a numeric score is assigned between 0-4, where 0 = Normal, 1 = Slight, 2 = Mild, 3 = Moderate, 4 = Severe. MDS-UPDRS Parts II and III combined score equals the sum of Part II and III (Range 0-184). A higher score indicates more severe symptoms of PD.
Time Frame
From Baseline up to Week 48
Title
Time to Confirmed Worsening in Modified Schwab and England Activities of Daily Living Scale (mSE-ADL) Over the Treatment Period
Description
Time to confirmed worsening is defined as a worsening event sustained over 2 consecutive assessments. The mSE-ADL scale reflects the speed, ease, and independence with which an individual performs daily activities or personal chores with 100% indicating total independence, falling to 0%, which indicates a state of complete dependence. The individual is asked to rate his or her function using an 11-point scale (10% increments), from 100% (completely independent; able to do all chores without slowness, difficulty, or impairment; essentially normal; unaware of any difficulty) to 0% (vegetative functions such as swallowing, bladder and bowels are not functioning; bedridden). The lower the score, the worse the functional status.
Time Frame
Up to a minimum of 48 weeks and a maximum of 144 weeks
Title
Change From Baseline in MDS-UPDRS Parts I, II, and III Combined Score
Description
MDS-UPDRS is a multimodal scale assessing impairment and disability consisting of 4 parts. Part I assesses non-motor experiences of daily living and has 2 components (Range 0-52). Part IA contains 6 questions and is assessed by the examiner (Range 0-24). Part IB contains 7 questions on non-motor experiences of daily living which are to be completed by the participant (Range 0-28). Part II assesses motor experiences of daily living (Range 0-52). It contains 13 questions which are to be completed by the participant. Part III assesses the motor signs of PD and is administered by the rater (Range 0-132). Part III contains 33 scores based on 18 items. For each question a numeric score is assigned between 0-4, where 0 = Normal, 1 = Slight, 2 = Mild, 3 = Moderate, 4 = Severe. MDS-UPDRS total score equals the sum of Parts I, II, and III (Range 0-236). A higher score indicates more severe symptoms of PD.
Time Frame
From Baseline up to Week 48
10. Eligibility
Sex
All
Minimum Age & Unit of Time
30 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Key Inclusion Criteria:
Clinical diagnosis of PD meeting the Movement Disorder Society Clinical Diagnostic Criteria within 2 years of the Screening Visit, inclusive, and at least 30 years of age at the time of diagnosis
Modified Hoehn and Yahr scale stages 1 to 2 (in OFF state), inclusive, at screening
MDS-UPDRS Parts II and III (in OFF state) combined score less than or equal to (≤)40 at screening
Key Exclusion Criteria:
Clinically significant neurological disorder other than PD, including but not limited to stroke, dementia, or seizure, within 5 years of screening visit, in the opinion of the Investigator
Clinical evidence of atypical parkinsonism (e.g., multiple-system atrophy or progressive supranuclear palsy) or evidence of drug-induced parkinsonism.
Montreal Cognitive Assessment (MoCA) score <24 at the screening visit.
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
US Biogen Clinical Trial Center
Phone
866-633-4636
Email
clinicaltrials@biogen.com
First Name & Middle Initial & Last Name or Official Title & Degree
Global Biogen Clinical Trial Center
Email
clinicaltrials@biogen.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Medical Director
Organizational Affiliation
Biogen
Official's Role
Study Director
Facility Information:
Facility Name
Mayo Clinic Arizona
City
Phoenix
State/Province
Arizona
ZIP/Postal Code
85054
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
480-342-3005
First Name & Middle Initial & Last Name & Degree
Erika Driver-Dunkley
Facility Name
Banner Sun Health Research Institute
City
Sun City
State/Province
Arizona
ZIP/Postal Code
85351
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
623-832-6530
First Name & Middle Initial & Last Name & Degree
David Shprecher
Facility Name
Cedars Sinai
City
Los Angeles
State/Province
California
ZIP/Postal Code
90048
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
310-248-6704
First Name & Middle Initial & Last Name & Degree
Michele Tagliati
Facility Name
SC3 Research Group Inc.
City
Pasadena
State/Province
California
ZIP/Postal Code
91105
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
626-250-2070
First Name & Middle Initial & Last Name & Degree
Lorraine Purino
Facility Name
University of California San Francisco (UCSF)
City
San Francisco
State/Province
California
ZIP/Postal Code
94143
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
415-353-2211
First Name & Middle Initial & Last Name & Degree
Marta San Luciano Palenzuela
Facility Name
University of Colorado
City
Aurora
State/Province
Colorado
ZIP/Postal Code
80045
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
303-724-5000
First Name & Middle Initial & Last Name & Degree
Emily Forbes
Facility Name
CenExel Rocky Mountain Clinical Research
City
Englewood
State/Province
Colorado
ZIP/Postal Code
80113
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
856-566-9000
First Name & Middle Initial & Last Name & Degree
Rajeev Kumar
Facility Name
Institute for Neurodegenerative Disorders (IND)
City
New Haven
State/Province
Connecticut
ZIP/Postal Code
06510
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
203-401-4300
First Name & Middle Initial & Last Name & Degree
David Russell
Facility Name
Parkinson's Disease and Movement Disorders Center of Boca Raton
City
Boca Raton
State/Province
Florida
ZIP/Postal Code
33486
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
561-392-1818
Ext
x2
First Name & Middle Initial & Last Name & Degree
Stuart Isaacson
Facility Name
University of Miami
City
Miami
State/Province
Florida
ZIP/Postal Code
33136
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
305-790-4246
First Name & Middle Initial & Last Name & Degree
Jason H. Margolesky
Facility Name
Adventist Health System/Sunbelt, Inc.
City
Orlando
State/Province
Florida
ZIP/Postal Code
32803
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
407-303-5600
First Name & Middle Initial & Last Name & Degree
Anwar Ahmed
Facility Name
USF Health Byrd Institute
City
Tampa
State/Province
Florida
ZIP/Postal Code
33613
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
813-396-0606
First Name & Middle Initial & Last Name & Degree
Robert Hauser
Facility Name
Hawaii Pacific Neuroscience, LLC
City
Honolulu
State/Province
Hawaii
ZIP/Postal Code
96817
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
808-261-4476
First Name & Middle Initial & Last Name & Degree
Kore Liow
Facility Name
Northwestern University
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60611
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
312-503-2970
First Name & Middle Initial & Last Name & Degree
Danielle Larson
Facility Name
Rush University Medical Center
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60612
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
312-942-5157
First Name & Middle Initial & Last Name & Degree
Katie Kompoliti
Facility Name
University of Kansas Medical Center Research Institute, Inc.
City
Kansas City
State/Province
Kansas
ZIP/Postal Code
66160
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
913-588-1261
First Name & Middle Initial & Last Name & Degree
Rajesh Pahwa
Facility Name
Boston University Medical Center
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02118
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
617-638-7745
First Name & Middle Initial & Last Name & Degree
Marie-Helene Saint-Hilaire
Facility Name
Beth Israel Deaconess Medical Center
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02215
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
617-667-0519
First Name & Middle Initial & Last Name & Degree
Shabbir Merchant
Facility Name
Massachusetts General Hospital
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02421
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
617-726-5532
First Name & Middle Initial & Last Name & Degree
Anne-Marie Wills
Facility Name
Quest Research Institute
City
Farmington Hills
State/Province
Michigan
ZIP/Postal Code
48334
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
248-957-8940
First Name & Middle Initial & Last Name & Degree
Aaron Ellenbogen
Facility Name
Mount Sinai Beth Israel
City
New York
State/Province
New York
ZIP/Postal Code
10003
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
212-844-8888
First Name & Middle Initial & Last Name & Degree
Swan Matthew
Facility Name
Weill Medical College of Cornell University
City
New York
State/Province
New York
ZIP/Postal Code
10021
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
212-746-1685
First Name & Middle Initial & Last Name & Degree
Harini Sarva
Facility Name
Duke Movement Disorders Clinic
City
Durham
State/Province
North Carolina
ZIP/Postal Code
27705
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
919-668-2905
First Name & Middle Initial & Last Name & Degree
Sneha Mantri
Facility Name
The Cleveland Clinic Foundation
City
Cleveland
State/Province
Ohio
ZIP/Postal Code
44195
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
216-444-9715
First Name & Middle Initial & Last Name & Degree
Michal T. Gostkowski
Facility Name
UPHS
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19107
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
215-829-6500
First Name & Middle Initial & Last Name & Degree
Andrew Siderowf
Facility Name
University of Pittsburgh
City
Pittsburgh
State/Province
Pennsylvania
ZIP/Postal Code
15213
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
215-829-8593
First Name & Middle Initial & Last Name & Degree
Lana Chahine
Facility Name
Medical University of South Carolina
City
Charleston
State/Province
South Carolina
ZIP/Postal Code
29425
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
843-792-3223
First Name & Middle Initial & Last Name & Degree
Christine Cooper
Facility Name
Neurology Clinic, PC
City
Cordova
State/Province
Tennessee
ZIP/Postal Code
38018
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
901-747-1111
First Name & Middle Initial & Last Name & Degree
Kendrick Henderson
Facility Name
The Methodist Hospital Research Institute
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
713-363-8184
First Name & Middle Initial & Last Name & Degree
William Ondo
Facility Name
Virginia Commonwealth University Department of Neurology
City
Richmond
State/Province
Virginia
ZIP/Postal Code
23298
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
804-828-1981
First Name & Middle Initial & Last Name & Degree
Matthew Barrett
Facility Name
Evergreen Hospital Medical Center
City
Kirkland
State/Province
Washington
ZIP/Postal Code
98034
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
425-899-1000
First Name & Middle Initial & Last Name & Degree
Pinky Agarwal
Facility Name
Inland Northwest Research
City
Spokane
State/Province
Washington
ZIP/Postal Code
99202
Country
United States
Individual Site Status
Recruiting
Facility Contact:
Phone
509-960-2818
First Name & Middle Initial & Last Name & Degree
Jason Aldred
Facility Name
Medizinische Universität
City
Innsbruck
State/Province
Tyrol
ZIP/Postal Code
6020
Country
Austria
Individual Site Status
Recruiting
Facility Contact:
Phone
+4351250481498
First Name & Middle Initial & Last Name & Degree
Klaus Seppi
Facility Name
Klinik Ottakring
City
Vienna
ZIP/Postal Code
1160
Country
Austria
Individual Site Status
Recruiting
Facility Contact:
Phone
+431491502001
First Name & Middle Initial & Last Name & Degree
Walter Pirker
Facility Name
University of Calgary
City
Calgary
State/Province
Alberta
ZIP/Postal Code
T2N 1N4
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
Phone
8015852886
First Name & Middle Initial & Last Name & Degree
Camila Aquino
Facility Name
True North Clinical Research
City
Halifax
State/Province
Nova Scotia
ZIP/Postal Code
B3S 1M7
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
Phone
9024734327
First Name & Middle Initial & Last Name & Degree
Kerrie Schoffer
Facility Name
Toronto Western Hospital
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M5T 2S8
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
Phone
4166032581
First Name & Middle Initial & Last Name & Degree
Emily Swinkin
Facility Name
CHUM Centre de Recherche
City
Montreal
State/Province
Quebec
ZIP/Postal Code
H2L 4M1
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
Phone
5148908000
First Name & Middle Initial & Last Name & Degree
Nicolas Jodoin
Facility Name
Montreal Neurological Institute
City
Montreal
State/Province
Quebec
ZIP/Postal Code
H3A 2B4
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
Phone
5149348026
First Name & Middle Initial & Last Name & Degree
Anne-Louise Lafontaine
Facility Name
Xuanwu Hospital Capital Medical University
City
Beijing
State/Province
Beijing
ZIP/Postal Code
100053
Country
China
Individual Site Status
Recruiting
Facility Name
Beijing Hospital
City
Beijing
State/Province
Beijing
ZIP/Postal Code
100730
Country
China
Individual Site Status
Recruiting
Facility Name
Second Affiliated Hospital of Soochow University
City
Jiangsu
State/Province
Jiangsu
ZIP/Postal Code
215004
Country
China
Individual Site Status
Recruiting
Facility Name
West China Hospital, Sichuan University
City
Chengdu
State/Province
Sichuan
ZIP/Postal Code
610041
Country
China
Individual Site Status
Recruiting
Facility Name
Hôpital de la Timone
City
Marseille
State/Province
Bouches-du-Rhône
ZIP/Postal Code
13385
Country
France
Individual Site Status
Recruiting
Facility Contact:
Phone
33491384333
First Name & Middle Initial & Last Name & Degree
Jean Philippe Azulay
Facility Name
Hopital Purpan
City
Toulouse Cedex 09
State/Province
Haute Garonne
ZIP/Postal Code
TSA 40031
Country
France
Individual Site Status
Recruiting
Facility Contact:
Phone
33 (0)561 14 59 62
First Name & Middle Initial & Last Name & Degree
Olivier Rascol
Facility Name
Hopital Gui de Chauliac
City
Montpellier
State/Province
Herault
ZIP/Postal Code
34295
Country
France
Individual Site Status
Recruiting
Facility Contact:
Phone
3346733629
First Name & Middle Initial & Last Name & Degree
Christian Geny
Facility Name
CHU Rennes - Hopital Pontchaillou
City
Rennes
State/Province
Ille Et Vilaine
ZIP/Postal Code
35033
Country
France
Individual Site Status
Recruiting
Facility Contact:
Phone
33299289564
First Name & Middle Initial & Last Name & Degree
Sophie Drapier
Facility Name
CHU Clermont Ferrand - Hopital Gabriel Montpied
City
Clermont Ferrand Cedex
State/Province
Puy De Dome
ZIP/Postal Code
63003
Country
France
Individual Site Status
Recruiting
Facility Contact:
Phone
33473751600
First Name & Middle Initial & Last Name & Degree
Ana-Raquel Marques
Facility Name
Centre Hospitalier Universitaire de Lyon-Hospices Civils de Lyon-Hopital Pierre Wertheimer
City
Bron
State/Province
Rhone
ZIP/Postal Code
69500
Country
France
Individual Site Status
Recruiting
Facility Contact:
Phone
+33 825 08 25 69
First Name & Middle Initial & Last Name & Degree
Stephane Thobois
Facility Name
CHU Nantes - Hopital Nord Laën
City
Loire-Atlantique
ZIP/Postal Code
44093
Country
France
Individual Site Status
Recruiting
Facility Contact:
Phone
33240165285
First Name & Middle Initial & Last Name & Degree
Philippe Damier
Facility Name
Groupe Hospitalier Pitie-Salpetriere
City
Paris
ZIP/Postal Code
75013
Country
France
Individual Site Status
Recruiting
Facility Contact:
Phone
33142165766
First Name & Middle Initial & Last Name & Degree
Jean Christophe Corvol
Facility Name
Hopital Henri Mondor
City
Paris
ZIP/Postal Code
94010
Country
France
Individual Site Status
Recruiting
Facility Contact:
Phone
33149812459
First Name & Middle Initial & Last Name & Degree
Philippe Remy
Facility Name
Universitat Ulm
City
Ulm
State/Province
Baden Wuerttemberg
ZIP/Postal Code
89081
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
Phone
4973150050980
First Name & Middle Initial & Last Name & Degree
Jan Kassubek
Facility Name
Katholisches Klinikum Bochum
City
Muenchen
State/Province
Bayern
ZIP/Postal Code
81675
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
Phone
498941404672
First Name & Middle Initial & Last Name & Degree
Lars Toenges
Facility Name
Universitaetsklinikum Wuerzburg
City
Wuerzburg
State/Province
Bayern
ZIP/Postal Code
97080
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
Phone
4993120123751
First Name & Middle Initial & Last Name & Degree
Jens Volkmann
Facility Name
Medizinische Hochschule Hannover
City
Hannover
State/Province
Niedersachsen
ZIP/Postal Code
30625
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
Phone
49511532198
First Name & Middle Initial & Last Name & Degree
Gunter Hoglinger
Facility Name
Katholisches Klinikum Bochum gGmbH
City
Bochum
State/Province
Nordrhein Westfalen
ZIP/Postal Code
44791
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
Phone
492345092420
First Name & Middle Initial & Last Name & Degree
Alfons Schnitzler
Facility Name
Universitaetsklinikum Duesseldorf AoeR
City
Duesseldorf
State/Province
Nordrhein Westfalen
ZIP/Postal Code
40225
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
Phone
492118116756
First Name & Middle Initial & Last Name & Degree
Bernhard Haslinger
Facility Name
Universitaetsklinikum Carl Gustav Carus TU Dresden
City
Dresden
ZIP/Postal Code
01307
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
Phone
493514582524
First Name & Middle Initial & Last Name & Degree
Björn Falkenburger
Facility Name
Paracelsus-Elena-Klinik Kassel
City
Kassel
ZIP/Postal Code
34128
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
Phone
+495616009200
First Name & Middle Initial & Last Name & Degree
Brit Mollenhauer
Facility Name
Universitätsklinikum Marburg
City
Marburg
ZIP/Postal Code
35043
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
Phone
+49 6421 58 65439
First Name & Middle Initial & Last Name & Degree
Karla Eggert
Facility Name
Universitaetsklinikum Tuebinge
City
Tuebingen
ZIP/Postal Code
72074
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
Phone
4970710290
First Name & Middle Initial & Last Name & Degree
Thomas Gasser
Facility Name
Rabin Medical Center
City
Petah Tikva
ZIP/Postal Code
49100
Country
Israel
Individual Site Status
Recruiting
Facility Contact:
Phone
+972 3 9378218
First Name & Middle Initial & Last Name & Degree
Ruth Djaldetti
Facility Name
Center Chaim Sheba Medical Center
City
Ramat Gan
ZIP/Postal Code
5262000
Country
Israel
Individual Site Status
Recruiting
Facility Contact:
Phone
+972507746017
First Name & Middle Initial & Last Name & Degree
Tsvia Fay-Karmon
Facility Name
Tel Aviv Sourasky Medical Center
City
Tel Aviv
ZIP/Postal Code
64239
Country
Israel
Individual Site Status
Recruiting
Facility Contact:
Phone
+972306973949
First Name & Middle Initial & Last Name & Degree
Tanya Gurevich
Facility Name
I.R.C.C.S. Neuromed
City
Diego
State/Province
Centonze
ZIP/Postal Code
86077
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
Phone
39865929250
First Name & Middle Initial & Last Name & Degree
Diego Centonze
Facility Name
IRCCS-Institute of Neurological Sciences of Bologna
City
Bologna
ZIP/Postal Code
40139
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
Phone
390512092929
First Name & Middle Initial & Last Name & Degree
Pietro Cortelli
Facility Name
Azienda Ospedaliera Spedali
City
Brescia
ZIP/Postal Code
25123
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
Phone
390303995260
First Name & Middle Initial & Last Name & Degree
Alessandro Padovani
Facility Name
U.O. Neurologia I
City
Catania
ZIP/Postal Code
95123
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
Phone
+390953782783
First Name & Middle Initial & Last Name & Degree
Mario Zappia
Facility Name
Ospedale Clinicizzato SS. Annu
City
Chieti
ZIP/Postal Code
66100
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
Phone
+3286537740
First Name & Middle Initial & Last Name & Degree
Astrid Thomas
Facility Name
Ospedale San Raffaele
City
Milano
ZIP/Postal Code
20132
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
Phone
+390226435737
First Name & Middle Initial & Last Name & Degree
Massimo Filippi
Facility Name
AO Universitaria Pisana
City
Pisa
ZIP/Postal Code
56126
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
Phone
+39050993604
First Name & Middle Initial & Last Name & Degree
Roberto Ceravolo
Facility Name
IRCCS San Raffaele Pisana
City
Roma
ZIP/Postal Code
00163
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
Phone
+3908659291
First Name & Middle Initial & Last Name & Degree
Laura Vacca
Facility Name
Okinawa Prefectural Nanbu
City
Haeburu
State/Province
Okinawa
ZIP/Postal Code
901-1105
Country
Japan
Individual Site Status
Recruiting
Facility Name
NHO Asahikawa Medical Center
City
Asahikawa-shi
ZIP/Postal Code
070-8644
Country
Japan
Individual Site Status
Recruiting
Facility Name
Himeji Central
City
Himeji-shi
ZIP/Postal Code
672-8043
Country
Japan
Individual Site Status
Recruiting
Facility Name
Sendai Nishitaga National Hospital
City
Sendai-shi
ZIP/Postal Code
982-8555
Country
Japan
Individual Site Status
Recruiting
Facility Name
Juntendo University
City
Tokyo
ZIP/Postal Code
113-8431
Country
Japan
Individual Site Status
Recruiting
Facility Name
Brain Research Center Amsterdam
City
Amsterdam
ZIP/Postal Code
1081 GN
Country
Netherlands
Individual Site Status
Recruiting
Facility Contact:
Phone
31205662500
First Name & Middle Initial & Last Name & Degree
Rob de Bie
Facility Name
Radboudumc
City
Nijmegen
ZIP/Postal Code
6525 GA
Country
Netherlands
Individual Site Status
Recruiting
Facility Contact:
Phone
31243615202
First Name & Middle Initial & Last Name & Degree
Bastiaan Bloem
Facility Name
Brain Research Center Zwolle B.V.
City
Zwolle
ZIP/Postal Code
8025 AZ
Country
Netherlands
Individual Site Status
Recruiting
Facility Contact:
Phone
+31 38 202 6120
First Name & Middle Initial & Last Name & Degree
Teus Van Laar
Facility Name
Centrum Medyczne NeuroProtect
City
Warsaw
State/Province
Mazowieckie
ZIP/Postal Code
01-684
Country
Poland
Individual Site Status
Recruiting
Facility Contact:
Phone
+48226996015
First Name & Middle Initial & Last Name & Degree
Maciej Czarnecki
Facility Name
Centrum Medyczne Neuromed
City
Bydgoszcz
ZIP/Postal Code
85-163
Country
Poland
Individual Site Status
Recruiting
Facility Contact:
Phone
+48 513 904 844
First Name & Middle Initial & Last Name & Degree
Pawel Lisewski
Facility Name
Instytut Zdrowia dr Boczarska-Jedynak sp.z.o.o, Sp.K
City
Katowice
ZIP/Postal Code
40-588
Country
Poland
Individual Site Status
Recruiting
Facility Contact:
Phone
48501485317
First Name & Middle Initial & Last Name & Degree
Magdalena Boczarska-Jedynak
Facility Name
Nzoz Novo-Med
City
Katowice
ZIP/Postal Code
40-650
Country
Poland
Individual Site Status
Recruiting
Facility Contact:
Phone
48322030106
First Name & Middle Initial & Last Name & Degree
Tomasz Zielinski
Facility Name
MD Clinic Praga
City
Warszawa
ZIP/Postal Code
03-505
Country
Poland
Individual Site Status
Recruiting
Facility Contact:
Phone
48223265815
First Name & Middle Initial & Last Name & Degree
Dariusz Koziorowski
Facility Name
INSULA Centrum Badan Klinicznych
City
Warszawa
ZIP/Postal Code
04-965
Country
Poland
Individual Site Status
Recruiting
Facility Contact:
Phone
+48 793 640 320
First Name & Middle Initial & Last Name & Degree
Zanna Pastuszak Stepien
Facility Name
Hospital General de Catalunya
City
Sant Cugat del Valles
State/Province
Barcelona
ZIP/Postal Code
8190
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
Phone
34931751575
First Name & Middle Initial & Last Name & Degree
Ernest Balaguer Martinez
Facility Name
Clinica Universidad de Navarra
City
Pamplona
State/Province
Navarra
ZIP/Postal Code
31008
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
Phone
34948255400
First Name & Middle Initial & Last Name & Degree
Rosario Luquin Piudo
Facility Name
Complejo Hospitalario Universitario A Coruña
City
A Coruna
ZIP/Postal Code
15006
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
Phone
+34646173341
First Name & Middle Initial & Last Name & Degree
Diego Santos García
Facility Name
Hospital de Cruces
City
Barakaldo
ZIP/Postal Code
48903
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
Phone
+34946006363
First Name & Middle Initial & Last Name & Degree
Juan Carlos Gomez Esteban
Facility Name
Hospital Universitari Vall d'Hebron
City
Barcelona
ZIP/Postal Code
8035
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
Phone
+34932746235
First Name & Middle Initial & Last Name & Degree
Jorge Hernandez-Vara
Facility Name
Hospital Clinic de Barcelona
City
Barcelona
ZIP/Postal Code
8036
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
Phone
34932275785
First Name & Middle Initial & Last Name & Degree
Marta Ferrer Puga
Facility Name
Hospital de la Santa Creu i Sant Pau
City
Barcelona
ZIP/Postal Code
8041
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
Phone
34935537117
First Name & Middle Initial & Last Name & Degree
Jaime Kulisevsky
Facility Name
Hospital Universitario de La Princesa
City
Madrid
ZIP/Postal Code
28006
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
Phone
+34915202416
First Name & Middle Initial & Last Name & Degree
Lydia Lopez Manzanares
Facility Name
Policlinica Gipuzkoa
City
San Sebastian
ZIP/Postal Code
20014
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
Phone
+34943002839818
First Name & Middle Initial & Last Name & Degree
Gurutz Linazasoro Cristobal
Facility Name
Hospital Universitario Virgen del Rocio
City
Sevilla
ZIP/Postal Code
41013
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
Phone
34955923039
First Name & Middle Initial & Last Name & Degree
Pablo Mir Rivera
Facility Name
University Hospitals Plymouth
City
Plymouth
State/Province
Devon
ZIP/Postal Code
PL6 8DH
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
Phone
+4407810485465
First Name & Middle Initial & Last Name & Degree
Stephen Mullin
Facility Name
The National Hospital for Neurology & Neurosurgery
City
London
State/Province
Greater London
ZIP/Postal Code
WC1N 3BG
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
Phone
+448451555000
First Name & Middle Initial & Last Name & Degree
Huw Morris
Facility Name
Salford Royal NHS Foundation Trust
City
Salford
State/Province
Greater Manchester
ZIP/Postal Code
M6 8HD
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
Phone
+44 16 12 06 05 34
First Name & Middle Initial & Last Name & Degree
Montague Silverdale
Facility Name
Glasgow Memory Clinic Ltd
City
Motherwell
State/Province
Strathclyde
ZIP/Postal Code
ML1 4UF
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
Phone
441412012486
First Name & Middle Initial & Last Name & Degree
Donald Grosset
Facility Name
Newcastle University
City
Newcastle upon Tyne
State/Province
Tyne And Wear
ZIP/Postal Code
NE4 5PL
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
Phone
+448448115522
First Name & Middle Initial & Last Name & Degree
Nicola Pavese
Facility Name
Ninewells Hospital
City
Dundee
ZIP/Postal Code
DD1 9SY
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
Phone
441382660111
First Name & Middle Initial & Last Name & Degree
Esther Sammler
12. IPD Sharing Statement
Plan to Share IPD
Yes
IPD Sharing Plan Description
In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on https://www.biogentrialtransparency.com/
IPD Sharing URL
https://vivli.org/
Links:
URL
https://www.parkinsonsresearchstudies.com/
Description
Click here to learn more about this trial, visit our study website.
Learn more about this trial
A Study to Assess the Safety of BIIB122 Tablets and if it Can Slow the Worsening of Early-Stage Parkinson's Disease in Participants Between the Ages of 30 and 80
We'll reach out to this number within 24 hrs